Th1 cell-mediated immune response (Th1 response)

The Th1 cell-mediated immune response is a specialized arm of the adaptive immune system characterized by the activation and differentiation of T helper 1 (Th1) cells [Assay Genie, NIH]. This process is primarily driven by the cytokine interleukin-12 (IL-12) and the master transcription factor T-bet, leading to the production of signature cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α) [R&D Systems, Creative Proteomics]. These cytokines are essential for coordinating host defenses against intracellular pathogens, including viruses and bacteria like Mycobacterium tuberculosis, by activating macrophages and promoting cytotoxic T lymphocyte (CTL) activity [Creative BioMart, Thermo Fisher]. However, an exaggerated or dysregulated Th1 response is a key driver of various autoimmune and inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis [Dr.Oracle, R&D Systems]. Therapeutic strategies often target this response by inhibiting its key cytokines (e.g., TNF-alpha, IL-12) or their downstream signaling pathways (e.g., JAK-STAT) to alleviate chronic inflammation [Dr.Oracle, PNAS]. Note: This entry describes a biological process/pathway rather than a single molecular target.

Other names

Type 1 immune responseT helper 1 cell-mediated immunityTh1 immunityCell-mediated immunity (Type 1)

Modulation of Th1 cell differentiation and effector function through inhibition of key cytokines (e.g., IL-12, TNF-alpha) or signaling pathways (e.g., JAK-STAT).